• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Unicycive Therapeutics Inc.

    10/11/24 4:02:13 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UNCY alert in real time by email
    SC 13G 1 uncy1011241sc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    Unicycive Therapeutics, Inc.
    (Name of Issuer)
     
    Common Stock, $0.001 par value
    (Title of Class of Securities)

     

    90466Y103  
      (CUSIP Number)  
     
    September 30, 2024
    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      x Rule 13d-1(b)
         
      o Rule 13d-1(c)
         
      o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     Page 1 of 9 
     

     

    CUSIP No.  90466Y103
    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Octagon Capital Advisors LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

    (a)o

    (b)o

    3

    SEC® USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    8,559,000

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    8,559,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    8,559,000

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    x1

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.1%

    12

    TYPE OF REPORTING PERSON (see instructions)

     

    IA, PN

     

    1 In addition to an aggregate of 8,559,000 shares of the Issuer's common stock (the "Common Stock") held outright (as a result of the conversion of preferred stock immediately upon effective registration of the Issuer's S-3), the reporting persons hold in the aggregate preferred stock (the "Preferred Stock") that may convert into an additional 1,441,000 shares of Common Stock. However, the provisions of such Preferred Stock restrict the conversion of such Preferred Stock to the extent that, after giving effect to such conversion, the holder of the Preferred Stock and its affiliates, together with any other person or entities with which such holder would constitute a group, would beneficially own in excess of 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion (the "Beneficial Ownership Cap"). As a result, no shares underlying such Preferred Stock are beneficially owned by the reporting persons at this time.

     

     Page 2 of 9 
     

     

    CUSIP No.  90466Y103
    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Octagon Investments Master Fund LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

    (a)o

    (b)o

    3

    SEC® USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    5,563,000

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    5,563,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,563,000

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    x1

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.9%

    12

    TYPE OF REPORTING PERSON (see instructions)

     

    OO, PN

     

    1 In addition to 5,563,000 shares of the Issuer's common stock (the "Common Stock") held outright (as a result of the conversion of preferred stock immediately upon effective registration of the Issuer's S-3), the Master Fund holds preferred stock (the "Preferred Stock") that may convert into an additional 937,000 shares of Common Stock. However, the provisions of such Preferred Stock restrict the conversion of such Preferred Stock to the extent that, after giving effect to such conversion, the holder of the Preferred Stock and its affiliates, together with any other person or entities with which such holder would constitute a group, would beneficially own in excess of 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion (the "Beneficial Ownership Cap"). As a result, no shares underlying such Preferred Stock are beneficially owned by the Master Fund at this time.

     

     Page 3 of 9 
     

     

    CUSIP No.  90466Y103
    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Octagon Private Opportunities Fund II LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

    (a)o

    (b)o

    3

    SEC® USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    2,996,000

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    2,996,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,996,000

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    x1

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.2%

    12

    TYPE OF REPORTING PERSON (see instructions)

     

    OO, PN

     

    1 In addition to 2,996,000 shares of the Issuer's common stock (the "Common Stock") held outright (as a result of the conversion of preferred stock immediately upon effective registration of the Issuer's S-3), the Private Fund II holds preferred stock (the "Preferred Stock") that may convert into an additional 504,000 shares of Common Stock. However, the provisions of such Preferred Stock restrict the conversion of such Preferred Stock to the extent that, after giving effect to such conversion, the holder of the Preferred Stock and its affiliates, together with any other person or entities with which such holder would constitute a group, would beneficially own in excess of 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion (the "Beneficial Ownership Cap"). As a result, no shares underlying such Preferred Stock are beneficially owned by the Private Fund II at this time.

     

     Page 4 of 9 
     

     

    CUSIP No.  90466Y103
    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Ting Jia

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

    (a)o

    (b)o

    3

    SEC® USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    China

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    8,559,000

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    8,559,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    8,559,000

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    x1

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.1%

    12

    TYPE OF REPORTING PERSON (see instructions)

     

    HC, IN

     

    1 In addition to an aggregate of 8,559,000 shares of the Issuer's common stock (the "Common Stock") held outright (as a result of the conversion of preferred stock immediately upon effective registration of the Issuer's S-3), the reporting persons hold in the aggregate preferred stock (the "Preferred Stock") that may convert into an additional 1,441,000 shares of Common Stock. However, the provisions of such Preferred Stock restrict the conversion of such Preferred Stock to the extent that, after giving effect to such conversion, the holder of the Preferred Stock and its affiliates, together with any other person or entities with which such holder would constitute a group, would beneficially own in excess of 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion (the "Beneficial Ownership Cap"). As a result, no shares underlying such Preferred Stock are beneficially owned by the reporting persons at this time.

     

     Page 5 of 9 
     

     

    Item 1(a). Name of Issuer:
       
       Unicycive Therapeutics, Inc.
       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
       
       4300 El Camino Real, Suite 210, Los Altos, CA 94022
       
    Item 2(a). Name of Person Filing:
       
      

    This statement is being jointly filed by:

     

    Octagon Capital Advisors LP ("Octagon")

    Octagon Investments Master Fund LP ("Master Fund")

    Octagon Private Opportunities Fund II LP ("Private Fund II")

    Ting Jia, as the principal beneficial owner of Octagon ("Mr. Jia")

     

    Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."

     

    Octagon serves as the investment manager of the Master Fund and the Private Fund II. Mr. Jia is the managing member of Octagon. By virtue of these relationships each of Octagon and Mr. Jia may be deemed to beneficially own the Issuer's Common Stock directly owned by the Master Fund and by the Private Fund II.

     

       
    Item 2(b). Address of Principal Business Office or, if none, Residence:
         
       The address of the business office of each of the Reporting Persons is 654 Madison Avenue, 21st Floor, New York, NY 10065
       
    Item 2(c). Citizenship:
       
       Octagon is a Delaware limited partnership. The Master Fund is an exempted limited partnership established in the Cayman Islands. The Private Fund II is a Delaware limited partnership. Mr. Jia is a Chinese citizen.
       
    Item 2(d). Title of Class of Securities:
       
       Common Stock, $0.001 par value (the "Common Stock)
       
    Item 2(e). CUSIP Number:  90466Y103

     

     Page 6 of 9 
     

     

    Item 3. If this Statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
      (a) o Broker or dealer registered under Section 15 of the Act;
      (b) o Bank as defined in Section 3(a)(6) of the Act;
      (c) o Insurance company as defined in Section 3(a)(19) of the Act;
      (d) o Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) o An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
      (g) x A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
      (h) o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
      (j) o A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
      (k) o Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:      

     

    Item 4. Ownership.
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       (a) Amount Beneficially Owned: 8,559,000
       (b)

    Percent of Class:

    The percentage reported on this Schedule 13G is calculated based upon 94,356,212 Common Stock

    outstanding as of August 14, 2024, as reported in the Form 10-Q filed by the Issuer on August 14, 2024.

    9.1%
       (c) Number of shares as to which such person has:
          (i) sole power to vote or to direct the vote: 0
          (ii) shared power to vote or to direct the vote: 8,559,000
          (iii) sole power to dispose or to direct the disposition of: 0
          (iv) shared power to dispose or to direct the disposition of: 8,559,000

     

     Page 7 of 9 
     

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
       If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.
       
     Item 6. Ownership of More than Five Percent on Behalf of Another Person.
       
       Octagon is the investment advisor to the Master Fund, the Private Fund II and other accounts. Mr. Jia is the control person of Octagon. The Master Fund holds the Common Stock for the benefit of its investors. The Private Fund II holds the Common Stock for the benefit of its investors. The Master Fund, the Private Fund II and Octagon, for the benefit of its investors, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
       
       Not applicable.
       
    Item 8. Identification and Classification of Members of the Group.
       
       Not applicable.
       
    Item 9. Notice of Dissolution of Group.
       
       Not applicable.
       
    Item 10. Certification.
       
       By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     Page 8 of 9 
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: October 11, 2024 OCTAGON CAPITAL ADVISORS LP
       
      /s/ Ting Jia
      Name: Ting Jia
      Title: Managing Member

     

     

     

      OCTAGON INVESTMENTS MASTER FUND LP
      By: Octagon Investments GP, LLC, its general partner
       
      /s/ Ting Jia
      Name: Ting Jia
      Title: Managing Member

     

     

     

     

    OCTAGON PRIVATE OPPORTUNITIES FUND II LP

    By: Octagon Investments GP, LLC, its general partner

     

    /s/ Ting Jia

      Name: Ting Jia
      Title: Managing Member

     

     

     

     

    TING JIA

     

    /s/ Ting Jia

      Name: Ting Jia

     

     

    Pages 9 of 9

     

     

     

    Get the next $UNCY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $UNCY

    DatePrice TargetRatingAnalyst
    4/21/2025$6.00Buy
    Guggenheim
    4/4/2024$9.00Overweight
    Piper Sandler
    8/9/2021$13.50Buy
    Roth Capital
    More analyst ratings

    $UNCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Aggarwal Gaurav converted options into 1,400,000 shares (SEC Form 4)

      4 - Unicycive Therapeutics, Inc. (0001766140) (Issuer)

      2/19/25 11:55:27 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Aggarwal Gaurav converted options into 5,500,000 shares (SEC Form 4)

      4 - Unicycive Therapeutics, Inc. (0001766140) (Issuer)

      10/10/24 5:15:20 PM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Townsend John

      4 - Unicycive Therapeutics, Inc. (0001766140) (Issuer)

      8/14/24 4:15:20 PM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UNCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Unicycive Therapeutics with a new price target

      Guggenheim initiated coverage of Unicycive Therapeutics with a rating of Buy and set a new price target of $6.00

      4/21/25 8:39:22 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Unicycive Therapeutics with a new price target

      Piper Sandler initiated coverage of Unicycive Therapeutics with a rating of Overweight and set a new price target of $9.00

      4/4/24 8:18:34 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital initiated coverage on Unicycive Therapeutics with a new price target

      Roth Capital initiated coverage of Unicycive Therapeutics with a rating of Buy and set a new price target of $13.50

      8/9/21 9:57:19 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UNCY
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $UNCY
    Leadership Updates

    Live Leadership Updates

    See more

    $UNCY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $UNCY
    SEC Filings

    See more
    • Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

      - Oxylanthanum carbonate (OLC) New Drug Application (NDA) for hyperphosphatemia in chronic kidney disease patients on dialysis under review by FDA with PDUFA target action date of June 28, 2025; ongoing commercial planning in preparation for anticipated commercial launch in late 2025 - New data from patient surveys and patient-reported outcomes studies highlight adherence challenges for patients with hyperphosphatemia on dialysis and emphasize the market potential of OLC LOS ALTOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial

      5/14/25 7:15:00 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

      LOS ALTOS, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, at 2:15 p.m. ET. A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. To request a 1x1 meeting with management, please contact your Needham representative. About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments f

      4/1/25 7:00:00 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update

            - Oxylanthanum carbonate (OLC) New Drug Application for hyperphosphatemia in chronic kidney disease patients on dialysis under review by the FDA with a PDUFA target action date of June 28, 2025 - Commercial planning in preparation for anticipated commercial launch of OLC in late 2025 LOS ALTOS, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended December 31, 2024, and provided a business update. "2025 is positioned to be a transformational year for Unicycive, with the near-term potential for

      3/31/25 7:00:00 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD

      LOS ALTOS, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced the appointment of Sara Kenkare-Mitra, PhD to the Company's Board of Directors, effective September 6, 2023. As a veteran of the biotech and pharmaceutical industry, we believe Sara's leadership and experience in drug development spanning more than 25 years will significantly help bolster Unicycive's future growth. "We are thrilled to welcome Dr. Kenkare-Mitra to our Board of Directors and know that her extensive drug development and corporate leadersh

      9/6/23 7:03:00 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Unicycive Therapeutics Appoints Douglas Jermasek As Executive Vice President, Corporate Strategy

      LOS ALTOS, Calif., Oct. 26, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the appointment of Douglas Jermasek as Executive Vice President, Corporate Strategy. In this role, Mr. Jermasek, a seasoned healthcare professional, will have responsibility for Unicycive's corporate and commercial strategy and business development activities. Doug has spent the majority of his career focused on drugs for treatment of kidney diseases"With a career spent in heal

      10/26/21 7:30:00 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

      SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

      11/14/24 7:13:38 PM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

      SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

      11/14/24 7:01:14 PM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

      SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

      11/14/24 5:46:12 PM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Unicycive Therapeutics Inc.

      SCHEDULE 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

      5/15/25 4:56:41 PM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Unicycive Therapeutics Inc.

      SCHEDULE 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

      5/15/25 4:39:09 PM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Unicycive Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Unicycive Therapeutics, Inc. (0001766140) (Filer)

      5/14/25 8:01:50 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UNCY
    Financials

    Live finance-specific insights

    See more
    • Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

      - Oxylanthanum carbonate (OLC) New Drug Application (NDA) for hyperphosphatemia in chronic kidney disease patients on dialysis under review by FDA with PDUFA target action date of June 28, 2025; ongoing commercial planning in preparation for anticipated commercial launch in late 2025 - New data from patient surveys and patient-reported outcomes studies highlight adherence challenges for patients with hyperphosphatemia on dialysis and emphasize the market potential of OLC LOS ALTOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial

      5/14/25 7:15:00 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update

            - Oxylanthanum carbonate (OLC) New Drug Application for hyperphosphatemia in chronic kidney disease patients on dialysis under review by the FDA with a PDUFA target action date of June 28, 2025 - Commercial planning in preparation for anticipated commercial launch of OLC in late 2025 LOS ALTOS, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended December 31, 2024, and provided a business update. "2025 is positioned to be a transformational year for Unicycive, with the near-term potential for

      3/31/25 7:00:00 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update

      – OLC New Drug Application (NDA) Accepted by the FDA with a PDUFA Target Action Date of June 28, 2025– – Commercial Planning in Progress for 2025 Launch – – Late Breaker Poster Presentation on OLC at ASN Kidney Week – – Successful Completion of UNI-494 Phase 1 Trial – LOS ALTOS, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY) (the "Company" or "Unicycive"), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the three months ended September 30, 2024, and provided a business update. "We are pleased with the

      11/13/24 7:15:00 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care